Co-Authors
This is a "connection" page, showing publications co-authored by Sergio Vaño-Galván and Andy Goren.
Connection Strength
2.653
-
Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial. Cureus. 2021 Feb 22; 13(2):e13492.
Score: 0.233
-
Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster. Med Hypotheses. 2021 01; 146:110439.
Score: 0.229
-
Reply to comment on: The Gabrin sign. J Am Acad Dermatol. 2021 03; 84(3):e149-e150.
Score: 0.229
-
5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. J Eur Acad Dermatol Venereol. 2021 Apr; 35(4):e243-e246.
Score: 0.229
-
Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients. J Eur Acad Dermatol Venereol. 2021 Jan; 35(1):e15-e17.
Score: 0.227
-
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. J Eur Acad Dermatol Venereol. 2021 Jan; 35(1):e13-e15.
Score: 0.227
-
Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign. J Am Acad Dermatol. 2020 12; 83(6):e453-e454.
Score: 0.224
-
Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? J Cosmet Dermatol. 2020 Jul; 19(7):1542-1543.
Score: 0.222
-
Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign". J Am Acad Dermatol. 2020 Aug; 83(2):680-682.
Score: 0.221
-
A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. 2020 Jul; 19(7):1545-1547.
Score: 0.220
-
What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. Dermatol Ther. 2020 Jul; 33(4):e13365.
Score: 0.219
-
Time of onset and duration of post-COVID-19 acute telogen effluvium. J Am Acad Dermatol. 2021 10; 85(4):975-976.
Score: 0.060
-
Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front Med (Lausanne). 2021; 8:668698.
Score: 0.060
-
Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res. 2020 11; 81(7):771-776.
Score: 0.055